Kusajili – Clinical trials directory

Result of your search per sponsor: IPSEN FARMACEUTICA BV

Man Max 99 years
IPSEN FARMACEUTICA BV Update Il y a 4 ans

PHASE II MULTI-CENTRIC, RANDOMISED, OPEN-LABEL, PARALLEL-GROUP STUDY TO ASSESS THE NON-INFERIORITY OF PAMORELIN® 11,25MG SC INJECTED VERSUS PAMORELIN® 11,25MG IM INJECTED IN PATIENTS SUFFERING FROM ADVANCED PROSTATE CANCER To assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via standard intra...

Country None
organs None
Specialty None

Closed trial

More information